121P Health-related quality of life (HRQoL) outcomes from CheckMate 77T: Neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant NIVO in resectable NSCLC
Year: 2024
Type: article
Abstract: CheckMate 77T (NCT04025879) demonstrated statistically significant and clinically meaningful improvement in event-free survival for perioperative NIVO added to neoadjuvant (neoadj) chemo (NIVO+chemo/NIVO) vs perioperative placebo added to neoadj chemo (chemo/PBO) in patients (pts) with resectable NSCLC. Here we report HRQoL results.
Source: ESMO Open
Authors: J. Spicer, M. Provencio Pulla, M. Awad, J. He, S. Lu, F. Tanaka, R. Cornelissen, L.B. Petruzelka, J. Kuzdzal, L. Wu, J-L. Pujol, H. Ito, T-E. Ciuleanu, L.D.O.M. Koch, A. Janssens, S.I. Blum, L. Vo, C. Coronado Erdmann, S. Meadows-Shropshire, T. Cascone
Institutions: McGill University Health Centre, Hospital Universitario Puerta de Hierro Majadahonda, Dana-Farber Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Shanghai Jiao Tong University, Shanghai Chest Hospital, University of Occupational and Environmental Health Japan, Erasmus MC Cancer Institute, Charles University, Jagiellonian University, John Paul II Hospital, Hunan Cancer Hospital, Centre Hospitalier Universitaire de Montpellier, Kanagawa Cancer Center, Iuliu Hațieganu University of Medicine and Pharmacy, Institute of Oncology Prof. Dr. Ion Chiricuta, Hospital Israelita Albert Einstein, Antwerp University Hospital, Bristol-Myers Squibb (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,730
OpenAlex ID: W4393166279